Fingolimod Hydrochloride

Wells Fargo joins Johnson & Johnson as the most recent company sued over employee prescription drug price management. Wells Fargo is the most recent corporation to get sued, as alleged by former employees, for inadequately overseeing the price workers were forced to pay for prescription drug prices.In a class action lawsuit filed in federal court named Navarro et al v. Wells Fargo Company, employees say the company did not fulfill its fiduciary obligations. Under the Employee Retirement Income Security Act of 1974, employers are required to adequately manage employee benefits programs.The plaintiffs argue Wells Fargo’s management of the prescription drugs program resulted in higher premiums, out-of-pocket costs and limited wage growth because of the prices it agreed to pay Express Scripts, one of its pharmacy benefit managers, for generic drugs.Employees, they say in the suit, were forced to pay nearly $10,000 for a a prescription of fingolimod, used to treat multiple sclerosis, when the generic version could be purchased without insurance for less than a $1,000 at pharmacies like Cost Plus Drugs and Rite Aid. “No prudent fiduciary would agree to make its plan and participants/beneficiaries pay a price that is fifteen times higher than the price available to anyone who just walks into a pharmacy and pays without using their insurance,” the plaintiffs said in the lawsuit.Across approximately 300 generic drugs, Wells Fargo and Express Scripts made employees pay a markup on average of 114.97% what it costs pharmacies to obtain the drugs, the lawsuit alleges. For specialty drugs, employees said they paid a markup of 383% on average.Other prescriptions were far more expensive for employees at Express Scripts’ pharmacy Accredo. Bexarotene gel, available at Rite Aid for $3,750, cost employees nearly $70,000 from Accredo.“The price discrepancies noted herein are illustrative of a pervasive and systematic problem of unreasonable prescription drug charges, despite well-known alternatives available to defendants,” the lawsuit said. Plaintiffs in the lawsuit say Wells Fargo should have received better rates from Express Scripts or a different PBM, guided employees to more cost-effective options or utilized a pass-through PBM that doesn’t use spread pricing.Wells Fargo was also tagged with accusations that it should have operated with more expertise given its standing in the industry. Plaintiffs noted Wells Fargo publishes research on the economics of the pharma industry, hosts an annual healthcare conference with speakers from major PBMs, operates an employee benefits consulting practice and has publicly warned about rising prescription drug costs and business practices by Express Scripts.A similar lawsuit was filed against Johnson & Johnson in February by the same law firm, Fairmark Partners.“This case alleges that Wells Fargo has failed its employees once again, this time by agreeing to obviously unreasonable terms and prices with its PBM that cause workers to vastly overpay for prescription drugs,” said Michael Lieberman, an attorney with Fairmark Partners. “After years of scrutiny and with clear alternatives available, there are no excuses left for a large corporation like Wells Fargo to ignore its legal obligation to identify reasonable prescription drug coverage options for its employees.” Mark Cuban, founder of Cost Plus Drugs, said in a X post that this type of lawsuit can be expected to occur more often.“This lawsuit is going to happen over and over and over with self insured companies until they realize they have to drop their big 3 PBM and use a Pass Through PBM,” he said. “The good news is if they switch they will save money and get control of their claims data.”As well as the Wells Fargo health plan, top human resource employees were also named as defendants in the lawsuit.Wells Fargo and Express Scripts did not immediately respond to a request for comment from Fierce Healthcare.Aon, the broker for Wells Fargo, was also listed in the lawsuit. Express Scripts was not listed as a defendant.

None Authored By: David Fields, CEO, NavitusIn a time when drug prices are skyrocketing, imagine slashing a company's pharmacy costs by 28% in a single year. Sound impossible? The Texas Association of Counties was able to achieve this by utilizing a pharmacy benefit manager (PBM) with a transparent, pass-through model that's focused on keeping overall drug prices low. As the Navitus Annual Drug Trend Report reveals, this approach is saving companies millions.In traditional models, a PBM will create and take margin (“spread”) between what it pays the pharmacy and what it bills the client when members receive a prescription medication under their benefit. This margin creation also occurs with the collection and distribution of rebates, discounts and fees, where the PBM collects more than it passes along to the payor and uses this spread to improve profits.When PBMs hide the amount of spread they collect, patients have to pay more for drugs, because potential savings are diverted into PBM profits. The Federal Trade Commission recently published an interim report on Prescription Drug Middlemen, highlighting the impact PBMs have on the accessibility and affordability of prescription drugs. We applaud the FTC for shining a spotlight on this issue.While working in pharmacy benefit management, I've witnessed firsthand the challenges plans face in managing rising prescription drug costs. Our report found a 6.8% increase in overall commercial drug spending trend for 2023, with specialty drug spend rising 5.7%, and non-specialty up 7.9%. These trends were due to increasing use of costly brand medications. In particular, the use of non-specialty medications for diabetes and new specialty medications for inflammatory conditions and oncology significantly drove costs. Cost trend is the year-over-year increase in costs and is driven by both more people utilizing a drug plus the unit cost increase of a drug.While overall trends are up, 29% of our commercial clients saw a decrease in their prescription drug costs between 2022 and 2023, even with increases in both drug cost and utilization. These savings underscore the impact of a transparent, pass-through model in PBM services. Navitus is one of the rare PBMs that publishes a Drug Trend Report using actual cost data.The report uncovered several key factors driving spending in 2023:GLP-1 Medications: These costly drugs, including Ozempic (semaglutide) and Mounjaro (tirzepatide) are primarily used for diabetes management. They were the most significant contributors to increased spending after an explosion in interest from patients. Navitus uses a diagnosis check program to promote on-label use, which reduced prescription orders without a proper diagnosis by 30% for participating employers.Targeted Immunomodulators (TIMs) biosimilars: The introduction of adalimumab biosimilars provided up-front cost savings for clients who previously had to pay for brand-name Humira. Total cost was reduced by 20% with savings from biosimilars and Humira rebates passed through to clients. As competition increases in biosimilars, we expect to see further cost reductions and improved transparency in this category.Attention-Deficit/Hyperactivity Disorder (ADHD): While a generic version of Vyvanse (lisdexamfetamine), a popular treatment for ADHD, was released in 2023, drug shortages reduced competition and limited the opportunity for cost savings. Product shortages and an increased utilization trend of 3% resulted in an overall cost trend of 4%.Specialty Medications: Generic launches in multiple sclerosis (MS) and high generic utilization in oncology offered significant cost-saving opportunities. Generic utilization within the MS category exceeded 60%, including generic options for Gilenya (fingolimod) and Aubagio (teriflunomide). As a result, there was a nearly 20% decrease in overall cost across the category.Today, traditional PBMs can use vertical integration and co-ownership to obscure profits while keeping drug prices high. In contrast, Navitus' transparent model directly passes through all rebates so plan sponsors and health plans can see the true cost of brand-name and generic drugs. Clients receive full access to their data – to the individual claim level – enabling them to understand the cost and value of their benefit and optimize it. Navitus customer Texas Association of Counties, found that after switching to Navitus in 2019, the organization has reduced pharmacy costs by $160 million in only five years.By utilizing strategies that drive to the lowest cost, companies that embrace transparency help reduce drug spend costs for plans and their members. There have been tremendous advances in care due to the release of new drugs. It’s our job to do everything we can to make these drugs affordable by not adding cost to the system, so that patients can access them. In the end, we believe that plan sponsors that embrace transparency today will be best positioned to reap the rewards of lower costs and healthier members tomorrow.